Influence of atorvastatin combining Tongxinluo Capsules on hypertensive artery disease and left ventricular hypertrophy

LIU Yong-dong; GAO Kang; ZHANG Yan

doi:10.3969/j.issn.1674-4055.2015.05.16

Abstract：Objective To observe the influence of atorvastatin combining Tongxinluo Capsules on hypertensive artery disease and left ventricular hypertrophy in patients with primary hypertension.Methods The patients (n=136) were chosen from Mar. 2013 to Sept. 2014, and randomly divided into Tongxinluo group (n=68, male 39 and female 29) treated with Tongxinluo Capsules and combined group (n=68, male 37 and female 31) treated with Tongxinluo Capsules and atorvastatin for 24w. The blood pressure (BP), EPFV, APFV and E/A were compared before and after treatment. The levels of LDL-C, HDL-C, TG, TC, ox-LDL and hs-CRP were detected, and changes of carotid artery intima-media thickness (CA-IMT) and in-artery atherosclerotic plaque area were compared before and after treatment.Resutls After treatment, 24h average systolic blood pressure and 24h average diastolic blood pressure decreased in 2 group (allP<0.01). The levels of LDL-C, TG, TC, ox-LDL and hs-CRP decreased and level of HDL-C increased in combined group compared with Tongxinluo group after treatment (all P<0.05). Compared with the same group, CA-IMT and in-artery atherosclerotic plaque area decreased significantly in 2 groups after treatment (allP<0.01). CA-IMT [(1.13±0.05) mmvs. (1.42±0.06) mm] and in-artery atherosclerotic plaque area [(0.41±0.02) cm2vs. (0.73±0.06) cm2] were significantly lower in combined group than those in Tongxinluo group (allP<0.05). After treatment, EPFV and E/A increased significantly and APFV decreased in 2 group (allP<0.01). Compared with Tongxinluo group, EPFV [(62.38±2.44) cm/svs. (69.10 ±1.97) cm/s] and E/A [(0.90±0.430vs. (1.18±0.27)] increased significantly and APFV decreased [(65.27±2.06) cm/svs. (60.73±2.28) cm/s] in combined group after treatment (allP<0.05).Conclusion Atorvastatin combining Tongxinluo Capsules is better than only Tongxinluo Capsules in treatment of vessel disease and left ventricular hypertrophy in hypertensive patients.